Phase 2 N=73 Cognitive Stimulation
Substance Use Disorders
Primary: Working Memory — 0.86; 0.04 digits recalled
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=49 Cognitive Dysfunction in Parkinson's Disease
Parkinson's Disease
Primary: Change in Magnetoencephalography (MEG) Connectivity Measures
N/A N=35 Neural Bases of Cognitive Rehabilitation for Brain Injury
Brain Injury
Primary: Change From Baseline on a Composite Measure (Z-score) of Attention, Working Memory, and Executive Functions — 0.26; .01 Change to Z (composite) score
N/A N=95 Cognitive Dysfunction In Parkinson's
Parkinson's
Primary: Differences in Error Rates on the NBack Task Between Real and Sham Stimulation Trials — -0.79; -0.1 incorrect responses
Phase 3 N=1,498 Cognition in the Study of Tamoxifen and Raloxifene
Cognition · Aging
Primary: Mean Change From Baseline on the the Benton Visual Retention Test Scores by Treatment Group — -0.73; -1.41 Number of errors
Early Phase 1 N=10 Cognition, Age, and RaPamycin Effectiveness - DownregulatIon of thE mTor Pathway
Cognitive Impairment, Mild · Alzheimer Disease
Primary: Blood Brain Barrier Penetration of RAPA — 0 ng/ml
N/A N=121 Cognition Intervention Study Dortmund
Cognition - Other
Primary: Tonic Alertness (Mean Reaction Time) — 281; 279 Milliseconds — p=0.79
N/A N=110 Cognition and Psychotherapy in PTSD
Posttraumatic Stress Disorder (PTSD)
Primary: Change in PTSD Checklist (PCL-5) — 9.25; 11.94; 15.91 change in units on a scale
N/A N=75 Cognitive Behavior Therapy and Work Outcome
Schizophrenia
Primary: Work Quality — 3.01; 3.23; 3.33 scores on a scale
N/A N=40 Preventing Cognitive Decline
Cognitive Decline
Primary: Percentage of Trials Correct On Working Memory Test — 87.69; 91.57; 88.01; 91.68 percentage of correct trials — p=>0.05
N/A N=20 Cognition and Magnetic Resonance Imaging of Brain Inflammation in Obesity
Obesity
Primary: Brain Inflammation Metrics in Obese and Normal-weight Individuals as Measured by Magnetic Resonance Image-based Diffusion Basis Spectrum Imaging (DBSI) — .0468; .0492…
Early Phase 1 N=124 Boost Study 21270 (Cognition)
Cognitive Function Abnormal
Primary: Task Completion Rate — 66; 57 Percentage of eligible participants
N/A N=6 Cognitive Rehab for Parkinson's
Parkinson's Disease · Mild Cognitive Impairment
Primary: Change in NIH Sponsored Executive Abilities: Measures and Instruments for Neurobehavioral Evaluation and Research (NIH-EXAMINER) Executive Composite Score — 0.34; -.42…
N/A N=72 Treatment to Enhance Cognition in Bipolar Disorder
Bipolar Disorder · Psychosis
Primary: MATRICS Consensus Cognitive Battery (MCCB) — 45.2; 45.5; 47.7; 49.3 T-scores
N/A N=69 Cognitive Training for Patients With Schizophrenia
Schizophrenia · Schizoaffective Disorder · Other Primary Psychotic Disorders
Primary: UCSD Performance-based Skills Assessment Total Score (Measures Functional Capacity) — 82.7; 84.4 units on a scale
N/A N=20 Electrophysiologic Studies of Cognition in Epilepsy Patients
Drug-resistant Epilepsy
Primary: Heartbeat Evoked Potential (HEP) for Attention — -1.5 µV
N/A N=16 Cognition in Patients With Hypoglycemia, Without Diabetes
Hypoglycemia · Cognition
Primary: Assessment of Immediate Verbal Memory — 50; 48 RAVLT scores on a scale (range 0 to 69) — p=0.90
N/A N=30 Cognitive Training in Parkinson's Disease
Parkinson Disease
Primary: Change in Quality of Life in Neurological Disorders Cognitive Function Version 2 (Neuro-QoL CF v2) T-scores at 6 Weeks — 49.9; 49.1; 50; 45.9 T-score — p=0.015
Phase 4 N=60 Characterizing and Predicting Drug Effects on Cognition
Cognitive Deficits
Primary: Change From Baseline in COWA Unique Word Count — -0.407725385; -0.425898667; -0.412534118; -0.108298333 Word Count
Phase 4 N=53 Treating Cognition in Schizophrenia With Atomoxetine and Cognitive Remediation
Cognition in Schizophrenia
Primary: Neuropsychological Measures for MATRICS — 20.82; 18.03; 25.43; 11.64 score on a scale
N/A N=60 Cognitive Markers in Prodromal MS
Multiple Sclerosis
Primary: Cerebral Metabolic Rate of Oxygen (CMRO2) — 8.17 micro-mol/100g/min
Phase 1 N=44 Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)
Alzheimer's Disease · Mild Cognitive Impairment
Primary: Change From Baseline in Averaged Correct Response Rate on the One Card Learning Task to Week 8 — 0.055; 0.034 Proportion of correct response
Phase 4 N=29 Modafinil Effects on Cognition in Schizophrenia Patients
Schizophrenia
Primary: Cognitive Performance — 76.7; 75.5; 67.2; 77.1 percentage correct of all trials
N/A N=31 Neuromodulation of Cognition in Older Adults
Healthy
Primary: Change in NIH Toolbox Fluid Cognition Composite Score — 4.7; 6.1 units on a scale
N/A N=51 Efficacy of Social Cognition Training in Schizophrenia
Schizophrenia
Primary: Social Cognitive Measures — 0.11; -1.68 score on a scale